A method name is not enough to establish that a test is suitable. Two laboratories can use the same general technology while applying different sample preparation, separation conditions, detectors and acceptance criteria. The question is whether the particular method can answer the research team's question reliably.

ICH Q2(R2), adopted in FDA guidance, describes validation characteristics selected according to the analytical procedure's intended purpose. The relevance of specificity, precision, accuracy and range depends on what the method is meant to measure. FDA ICH Q2 R2 analytical validation guidance

Define the decision first

A test intended to confirm identity has a different purpose from one intended to quantify a minor impurity. A method appropriate for a concentrated bulk material may not perform the same way in a dilute finished formulation. The surrounding matrix can matter as much as the target molecule.

Before commissioning a test, write the decision the result will support. For example, the question might be whether two lots are comparable for a sensitive cell assay, rather than whether one chromatogram looks cleaner. That framing helps the analyst select meaningful methods and controls.

Interpret absence cautiously

A result reported as not detected depends on the method's detection capability. It does not establish literal absence under all possible tests. Similarly, a pass result depends on an acceptance criterion that should have been defined before the result was known.

AXON's practical recommendation is to request a short method rationale in addition to the final number: what was measured, in which material, with what limitations, and against which criterion. This is a quality discussion for trained researchers, not instructions for preparing or administering a substance. A public supplier comparison should not imply that one instrument type alone proves superiority.